TY - JOUR
T1 - Human papillomavirus 16 E6 antibodies in individuals without diagnosed cancer
T2 - A pooled analysis
AU - Lang Kuhs, Krystle A.
AU - Anantharaman, Devasena
AU - Waterboer, Tim
AU - Johansson, Mattias
AU - Brennan, Paul
AU - Michel, Angelika
AU - Willhauck-Fleckenstein, Martina
AU - Purdue, Mark P.
AU - Holcátová, Ivana
AU - Ahrens, Wolfgang
AU - Lagiou, Pagona
AU - Polesel, Jerry
AU - Simonato, Lorenzo
AU - Merletti, Franco
AU - Healy, Claire M.
AU - Kjaerheim, Kristina
AU - Conway, David I.
AU - Macfarlane, Tatiana V.
AU - Thomson, Peter
AU - Castellsagué, Xavier
AU - Znaor, Ariana
AU - Black, Amanda
AU - Huang, Wen Yi
AU - Krogh, Vittorio
AU - Trichopoulou, Antonia
AU - Bueno-De-Mesquita, H. B A S
AU - Clavel-Chapelon, Françoise
AU - Weiderpass, Elisabete
AU - Ekström, Johanna
AU - Riboli, Elio
AU - Tjønneland, Anne
AU - Sánchez, María José
AU - Travis, Ruth C.
AU - Hildesheim, Allan
AU - Pawlita, Michael
AU - Kreimer, Aimée R.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Background: The increasing incidence of oropharyngeal cancer in many developed countries has been attributed to human papillomavirus type 16 (HPV16) infections. Recently, HPV16 E6 serology has been identified as a promising early marker for oropharyngeal cancer. Therefore, characterization of HPV16 E6 seropositivity among individuals without cancer is warranted. Methods: A total of 4,666 controls were pooled from several studies of cancer and HPV seropositivity, all tested within the same laboratory. HPV16 E6 seropositive controls were classified as having (i) moderate [mean fluorescent intensity (MFI) ≥ 484 and
AB - Background: The increasing incidence of oropharyngeal cancer in many developed countries has been attributed to human papillomavirus type 16 (HPV16) infections. Recently, HPV16 E6 serology has been identified as a promising early marker for oropharyngeal cancer. Therefore, characterization of HPV16 E6 seropositivity among individuals without cancer is warranted. Methods: A total of 4,666 controls were pooled from several studies of cancer and HPV seropositivity, all tested within the same laboratory. HPV16 E6 seropositive controls were classified as having (i) moderate [mean fluorescent intensity (MFI) ≥ 484 and
UR - http://www.scopus.com/inward/record.url?scp=84925848405&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925848405&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-14-1217
DO - 10.1158/1055-9965.EPI-14-1217
M3 - Article
AN - SCOPUS:84925848405
VL - 24
SP - 683
EP - 689
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
SN - 1055-9965
IS - 4
ER -